Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Files An 8-K Submission of Matters to a Vote of Security Holders

Item5.07

On May24, 2017, Alder BioPharmaceuticals, Inc. (the Company) held
its 2017 Annual Meeting of Stockholders at the offices of Cooley
LLP at 1700 Seventh Avenue, Suite 1900, Seattle, Washington,
98101 (the Annual Meeting). At the Annual Meeting, the Companys
stockholders voted on three proposals, each of which is described
in more detail in the Companys definitive proxy statement on
Schedule 14A filed with the Securities and Exchange Commission on
April28, 2017 (the Proxy Statement). The following is a brief
description of each matter voted upon and the certified voting
results.

Proposal No.1. Stockholders elected each of the three nominees
for ClassIII director to serve until the Companys 2020 Annual
Meeting of Stockholders and until his or her respective successor
has been duly elected and qualified, or, if sooner, until the
directors death, resignation or removal. The final voting results
were as follows:

Proposal No.2. Stockholders approved, on an advisory basis, the
compensation of the Companys named executive officers as
disclosed in the Proxy Statement. The final voting results were
as follows:

Proposal No.3. Stockholders ratified the selection by the Audit
Committee of the Companys Board of Directors of
PricewaterhouseCoopers LLP as the Companys independent registered
public accounting firm for the fiscal year ending December31,
2017. The final voting results were as follows:

About Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR)

Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company’s pipeline includes ALD403, Clazakizumab and ALD1613. ALD403 is the Company’s monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6), and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone, and is being developed for the treatment of Cushing’s disease. Its candidate, Eptinezumab, is an investigational product candidate being developed as a migraine prevention treatment for patients with chronic and frequent episodic migraine. It is also is developing ALD1910, a genetically engineered monoclonal antibody.

Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Recent Trading Information

Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) closed its last trading session down -0.90 at 16.15 with 581,673 shares trading hands.